Ushering in A New Wave of Progress in Advanced Hepatobiliary Cancers: Expert Perspectives on Incorporating New Evidence and Innovative Therapeutics to Deliver Optimal, Patient-Centered Care

In this animated activity, an expert in dermatology discusses new and novel therapies addressing unmet patient needs in the management of chronic spontaneous urticaria (CSU).

Despite the widespread use of surgery as a standard of care for tenosynovial giant cell tumor (TGCT), several therapeutic challenges remain, particularly in the setting of diffuse TGCT, where recurrent and difficult-to-treat disease can be present. In this activity, an orthopedic surgeon and medical oncologist debate the case-based management of challenging TGCT presentations, and illustrate the nuances of multidisciplinary collaboration when managing patients with TGCT. Throughout, the panelists profile a modern management synthesis that combines surgery, physical therapy, and the use of targeted agents, including for patients for whom surgery alone is unlikely to be beneficial.

In this activity, an expert in neurology discusses emerging treatment options for patients with amyotrophic lateral sclerosis.

In this activity, an expert dermatologist discusses the latest evidence from the 30th European Academy of Dermatology and Venereology Congress for current and emerging targeted biologic therapies for moderate to severe atopic dermatitis in adults and children.

In this activity, a hematology expert discusses the diagnostic assessment and management of von Willebrand disease, as well as available treatment options and strategies for shared decision-making.

This CME/NCPD/CPE activity includes five individual interactive, microlearning modules addressing care and outcomes for individuals with diabetes treated with mealtime insulin (MTI).  The modules incorporate case studies with embedded questions for an active learning experience. Learners can choose to participate in one or more of the modules to address their educational interests and needs based on their scope of practice and patient population.

This CME/NCPD/CPE activity includes five individual interactive, microlearning modules addressing care and outcomes for individuals with diabetes treated with mealtime insulin (MTI). The modules incorporate case studies with embedded questions for an active learning experience. Learners can choose to participate in one or more of the modules to address their educational interests and needs based on their scope of practice and patient population.

In this activity, a hematologist-oncologist, cardiologist, oncology nurse, and pharmacist team up to discuss targeted agents (including BTK and BCL-2 inhibitors) in B-cell malignancies and how the team works closely together to manage toxicity and safety concerns associated with targeted therapies. Case scenarios are presented to illustrate how a collaborative approach is not only necessary for managing patients with B-cell cancers, such as CLL and MCL, but can also improve patient outcomes through monitoring and managing adverse events.

An expert discusses the latest data on targeted treatments for biliary cancers and integrating precision medicine with new and emerging strategies.

After more than a decade of limited progress, the clinical management of advanced biliary tract cancers is rapidly changing. The introduction of new systemic therapies and the increased understanding of clinically actionable mutations in biliary tract cancers have led to the development of several biomarker-guided treatments and other promising strategies. In this activity, an oncology advanced practice provider discusses the latest clinical data regarding recently validated and forthcoming therapeutic strategies for patients with biliary tract cancers and the nurse’s role in improving patient outcomes through patient education, monitoring for and managing treatment-related toxicities, and counseling patients on therapeutic options, including clinical trial enrollment.